Mixed steatohepatitis: more questions than answers (Part 1)

Cover Page

Cite item

Full Text

Abstract

The term «steatohepatitis» is used for a heterogeneous group of diseases of various etiologies, characterized by a similar morphological picture. Earlier the diagnosis of non-alcoholic fatty liver disease implied the exclusion of other causes of steatohepatitis, in recent years it has been suggested that a combination of various etiological variants of steatohepatitis is possible. The review considers the terminological, epidemiological and pathogenetic aspects of the most common combination: metabolic and alcoholic genesis, the issues of the mutual influence of etiopathogenetic factors and the identification of the predominant process. Issues of existing and prospective pathogenetic and symptomatic therapy are discussed in detail. Treatment of steatohepatitis is based on the elimination of known causal factors and lifestyle modification; therapy includes medications, that have been proven to be effective in certain types of steatohepatitis and symptomatic therapy as well.

About the authors

K. L. Raikhelson

Scientific, Clinical and Educational Center of Gastroenterology and Hepatology, Saint Petersburg State University

Author for correspondence.
Email: kraikhelson@mail.ru
ORCID iD: 0000-0002-8821-6142

д.м.н., проф.

Russian Federation, Saint Petersburg

E. A. Kondrashina

Scientific, Clinical and Educational Center of Gastroenterology and Hepatology, Saint Petersburg State University

Email: kraikhelson@mail.ru
ORCID iD: 0000-0002-0142-0264

к.м.н., доц.

Russian Federation, Saint Petersburg

E. V. Pazenko

Scientific, Clinical and Educational Center of Gastroenterology and Hepatology, Saint Petersburg State University

Email: kraikhelson@mail.ru
ORCID iD: 0000-0002-7590-8932

мл. науч. сотр.

Russian Federation, Saint Petersburg

References

  1. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004
  2. Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2016;69(3):718-35. doi: 10.1016/j.jhep.2018.05.011
  3. Wandji LCN, Gnemmi V, Mathurin P, Louvet A. Combined alcoholic and non-alcoholic steatohepatitis. JHEP Reports.2020;2(3):100101. doi: 10.1016/j.jhepr.2020.100101
  4. Francque S, Vonghia L. Pharmacological Treatment for Non-alcoholic Fatty Liver Disease. Adv Ther. 2019;36:1052-74. doi: 10.1007/s12325-019-00898-6
  5. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi: 10.1002/hep.28431
  6. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-8.
  7. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74-80.
  8. Eslam M, Sanya AJ, George J. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014. doi: 10.1053/j.gastro.2019.11.312
  9. Becker U, Deis A, Sorensen TI, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996;23(5):1025-29. doi: 10.1002/hep.510230513
  10. Boyle M, Masson S, Anstee QM. The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. J Hepatol. 2018;68(2):251-67. doi: 10.1016/j.jhep.2017.11.006
  11. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132(2):112-7. doi: 10.7326/0003-4819-132-2-200001180-00004
  12. Маевская М.В., Бакулин И.Г., Чирков А.А. и др. Злопотребление алкоголем среди пациентов гастроэнтерологического профиля. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016;26(4):24-35 [Maevskaja MV, Bakulin IG, Chirkov AA, et al. Alcohol abuse among gastroenterological patients. Rus J Gastroenterol Hepatol Coloproctol. 2016;26(4):24-35 (In Russ.)]. doi: 10.22416/1382-4376-2016-26-4-24-35
  13. Speliotes EK, Yerges-Armstrong LM, Wu J, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011;7(3):e001324. doi: 10.1371/journal.pgen.1001324
  14. Chamorro AJ, Torres JL, Mirón-Canelo JA, et al. Systematic review with meta-analysis: the I148M variant of patatin-like phospholipase domain-containing 3 gene (PNPLA3) is significantly associated with alcoholic liver cirrhosis. Aliment Pharmacol Ther. 2014;40(6):571-81. doi: 10.1111/apt.12890
  15. Yang E, Trepo P, Nahon Q, et al. PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. Int J Cancer. 2019;144(3):533-44. doi: 10.1002/ijc.31910
  16. Buch S, Stickel F, Trepo E, et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet. 2015;47(12):1443-8. doi: 10.1038/ng.3417
  17. Nassir F, Rector S, Hammoud GM, Ibdah JA. Pathogenesis and prevention of hepatic steatosis. J Gastroenterol Hepatol. 2015;11(3):167-75.
  18. Ji C, Chan С, Kaplowitz N. Predominant role of sterol response element binding proteins (SREBP) lipogenic pathways in hepatic steatosis in the murne intragastric ethanol feeding model. J Hepatol. 2006;45(5):717-24. doi: 10.1016/j.jhep.2006.05.009
  19. Kohjima M, Higuchi N, Kato M, et al. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med. 2008;21(4):507-11.
  20. You M, Matsumoto M, Pacold CM, et al. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology. 2004;127(6):1798-808. doi: 10.1053/j.gastro.2004.09.049
  21. Adolph TE, Grander C, Grabherr F, Tilg H. Adipokines and non-alcoholic fatty liver disease: multiple interactions. Int J Mol Sci. 2017;18(8):1649. doi: 10.3390/ijms18081649
  22. Tang H, Sebastian BM, Axhemi A, et al. Ethanol-induced oxidative stress via the CYP2E1 pathway disrupts adiponectin secretion from adipocytes. Alcohol Clin Exp Res. 2012;36(2):214-22. doi: 10.1111/j.1530-0277.2011.01607.x
  23. Greuter T, Gores GJ, Shah VH. Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. JCI Insight. 2017;2(17):e95354. doi: 10.1172/jci.insight.95354
  24. Bashiardes S, Shapiro H, Rozin S, et al. Molecular Metabolism Non-alcoholic fatty liver and the gut microbiota. Mol Metabol. 2016;5(9):782-94. doi: 10.1016/j.molmet.2016.06.003
  25. Stärkel P, Leclercq S, de Timary P, Schnabl B. Intestinal dysbiosis and permeability: The yin and yang in alcohol dependence and alcoholic liver disease. Rev Clin Sci. 2018;132(2):199-212. doi: 10.1042/CS20171055
  26. Rivera CA, Adegboyega P, van Rooijen N, et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 2007;47(4):571-79. doi: 10.1016/j.jhep.2007.04.019
  27. Petrasek J, Csak T, Ganz M, Szabo G. Differences in innate immune signaling between alcoholic and non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2013;28(1):93-8. doi: 10.1111/jgh.12020
  28. Younossi ZM, Stepanova M, Ong J, et al. Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(8):1625-33. doi: 10.1016/j.cgh.2018.11.033
  29. Ekstedt M, Franzén LE, Holmqvist M, et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2009;44(3):366-74. doi: 10.1080/00365520802555991
  30. Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121:91-100. doi: 10.1053/gast.2001.25540
  31. Dunn W, Sanyal AJ, Brunt EM, et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol. 2012;57:384-91. doi: 10.1016/j.jhep.2012.03.024
  32. Hagstrom H, Nasr P, Ekstedt M, et al. Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2017;52:159-65. doi: 10.1080/00365521.2016.1239759
  33. Sookoian S, Castaño GO, Pirola CJ. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals. Gut. 2014;63(3):530-2. doi: 10.7717/peerj.2633
  34. Sookoian S, Flichman D, Castaño GO, Pirola CJ. Mendelian randomisation suggests no beneficial effect of moderate alcohol consumption on the severity of nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2016;44(11-12):1224-34. doi: 10.1111/apt.13828
  35. Cao G, Tingzhuang Yi, Liu Q, et al. Alcohol consumption and risk of fatty liver disease: a meta-analysis. PeerJ. 2016;4:e2633. doi: 10.7717/peerj.2633
  36. Ajmera VH, Terrault NA, Harrison SA. Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. Hepatology. 2017;65(6):2090-9. doi: 10.1002/hep.29055
  37. Ahmed A, James E. Rohrer Patterns of alcohol drinking and its association with obesity: data from the third national health and nutrition examination survey, 1988–1994. BMC Public Health. 2005;5:126. doi: 10.1186/1471-2458-5-126
  38. Moriya A, Iwasaki Y, Ohguchi S, et al. Roles of alcohol drinking pattern in fatty liver in Japanese women. Hepatol Int. 2013;7(3):859-68. doi: 10.1016/j.jhep.2014.11.025
  39. Yamada K, Mizukoshi E, Seike T, et al. Light alcohol consumption has the potential to suppress hepatocellular injury and liver fibrosis in non-alcoholic fatty liver disease. Plos One. 2018;13(1):e0191026. doi: 10.1371/journal.pone.0191026
  40. Baur A, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337-42. doi: 10.1038/nature05354
  41. Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology. 2008;47(6):1947-54. doi: 10.1002/hep.22292
  42. Ajmera V, Belt P, Wilson LA, et al. Nonalcoholic Steatohepatitis Clinical Research Network Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis. Clin Gastroenterol Hepatol. 2018;16(9):1511-20.e5. doi: 10.1016/j.cgh.2018.01.026
  43. Mulazzani L, Alvisi M, Goio E, et al. Moderate alcohol consumption is associated with higher gradeof liver fibrosis in patients with non-alcoholic fatty liver disease. Abstract book NAFLD summit 2019. Summit 2019, 26–28 September 2019, Seville, Spain. 2019:94. Accessed September 6, 2020. https://www.easl.eu/nafld2019/wp-content/uploads/2019/09/NAFLD-Summit-2019-Abstract-book.pdf
  44. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51(6):1972-8. doi: 10.1002/hep.23527
  45. Åberg F, Puukka P, Salomaa V, et al. Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-Up of Population Cohorts. Hepatology. 2020;71(3):835-48. doi: 10.1002/hep.30864
  46. Loomba CR, Yang HI, Su J, et al. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort stud. Am J Epidemiol. 2013;177(4):333-42. doi: 10.1093/aje/kws252
  47. Bush K, Kivlahan DR, McDonell MB, et al. The AUDIT alcohol consumption questions (AUDIT-C): An effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med. 1998;158(16):1789-95. doi: 10.1001/archinte.158.16.1789
  48. Wang J, Li P, Jiang Z, et al. Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD. Korean J Intern Med. 2016;31(3):479-87. doi: 10.3904/kjim.2015.253
  49. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating non-alcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999;94:1018. doi: 10.1111/j.1572-0241.1999.01006.x
  50. Dunn W, Angulo P, Sanderson S, et al. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology. 2006;131(4):1057-63. doi: 10.1053/j.gastro.2006.08.020
  51. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. и др. Клинические рекомендации Российского общества по изучению печени по ведению взрослых пациентов с алкогольной болезнью печени. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2017;27(6):20-40 [Ivashkin VT, Mayevskaya MV, Pavlov ChS, et al. Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society. Rus J Gastroenterol, Hepatol, Coloproctol. 2017;27(6):20-40 (In Russ.)]. doi: 10.22416/1382-4376-2017-27-6-20-40
  52. Клинические рекомендации: алкогольная болезнь печени у взрослых. Терапия. 2020;4:10-35 [Clinical recommendations: alcoholic liver disease in adult. Therapy. 2020;4:10-35 (In Russ.)]. doi: 10.18565/therapy.2020.4.10–35
  53. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018;69(1):154-81. doi: 10.1016/j.jhep.2018.03.018
  54. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016;2:24-42 [Ivashkin VT, Maevskaja MV, Pavlov ChS, et al. Clinical guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association. Rus J Gastroenterol Hepatol Coloproctol. 2016;2:24-42 (In Russ.)]. doi: 10.22416/1382-4376-2016-26-2-24-42
  55. Alkhouri N, Scott A. An update on the pharmacological treatment of nonalcoholic fatty liver disease: beyond lifestyle modifications. Clin Liver Dis. 2018;11(4):82-6. doi: 10.1002/cld.708
  56. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367-78. doi: 10.1053/j.gastro.2015.04.005
  57. Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57(1):157-66. doi: 10.1016/j.jhep.2012.02.023
  58. Kistler KD, Brunt EM, Clark JM, et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol. 2011;106(3):460-8. doi: 10.1038/ajg.2010.488
  59. Gepner Y, Shelef I, Komy O, et al. The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. J Hepatol. 2019;71(2):379-88. doi: 10.1016/j.jhep.2019.04.013
  60. Chalasani N, Younossi Z, Lavine JE, e al. Nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328-57. doi: 10.1002/hep.29367
  61. Burton R, Sheron N. No level of alcohol consumption improves health. Lancet. 2018;392(10152):987-88. doi: 10.1016/S0140-6736(18)31571-X
  62. Singal AK, Bataller R, Ahn J, et al. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol. 2018;113(2):175-94. doi: 10.1038/ajg.2017.469
  63. Liu Y-L, Patman GL, Leathart JBS, et al. Carriage of the PNPLA3 rs738409 polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol. 2017;61:75-81. doi: 10.1016/j.jhep.2014.02.030
  64. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-85. doi: 10.1056/NEJMoa0907929
  65. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305:1659-68. doi: 10.1001/jama.2011.520
  66. Pydyn N, Miękus K, Jura J, Kotlinowski J. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis. Pharmacol Rep. 2020;72:1-12. doi: 10.1007/s43440-019-00020-1
  67. Francque S, Vonghia L. Pharmacological Treatment for Non-alcoholic Fatty Liver Disease. Adv Ther. 2019;36:1052-74. doi: 10.1007/s12325-019-00898-6
  68. Younossi ZM. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184-96. doi: 10.1016/S0140-6736(19)33041-7
  69. Harrison SA, Goodman Z, Jabbar A, et al. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. J Hepatol. 2020;72(5):816-27. doi: 10.1016/j.jhep.2019.11.024
  70. GENFIT: Announces Results from Interim Analysis of RESOLVE-IT Phase 3 Trial of Elafibranor in Adults with NASH and Fibrosis. May 11, 2020. Accessed September 6, 2020. https://ir.genfit.com/news-releases/news-release-details/genfit-announces-results-interim-analysis-resolve-it-phase-3
  71. Harrison SA, Wai-Sun Wong V, Okanoue T, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol. 2020;73(1):26-39. doi: 10.1016/j.jhep.2020.02.027
  72. Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372(17):1619-28. doi: 10.1056/NEJMoa1412278
  73. Mato JM, Cámara J, Fernández de Paz J, et al. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30:1081-9. doi: 10.1016/s0168-8278(99)80263-3
  74. Elliott C, Frith J, Day CP, et al. Functional impairment in alcoholic liver disease and non-alcoholic fatty liver disease is significant and persists over 3 years of follow-up. Dig Dis Sci. 2013;58(8):2383-91. doi: 10.1007/s10620-013-2657-2
  75. Assimakopoulos K, Karaivazoglou K, Tsermpini EE, et al. Quality of life in patients with nonalcoholic fatty liver disease: A systematic review. J Psychosom Res. 2018;112:73-80. doi: 10.1016/j.jpsychores.2018.07.004
  76. Райхельсон К.Л., Кондрашина Э.А. Адеметионин в лечении повышенной утомляемости/слабости при заболеваниях печени: систематический обзор. Терапевтический архив. 2019;91(2):134-42 [Raikhelson KL, Kondrashina EA. Ademethionine in the treatment of fatigue in liver diseases: a systematic review. Therapeutic Archive. 2019;91(2):134-42 (In Russ.)]. doi: 10.26442/00403660.2019.02.000130
  77. Noureddin M, Sander-Struckmeier S, Mato JM. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review. World J Hepatol. 2020;12(2):46-63. doi: 10.4254/wjh.v12.i2.46
  78. Saigal S, Kapoor D, Roy DS. Ademetionine in patients with liver disease: a review. Int J Res Res Med Sci. 2019;7(6):2482-93: doi: 10.18203/2320-6012.ijrms20192550
  79. Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: Update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood). 2015;240(6):809-20. doi: 10.1177/1535370215579161
  80. Mato JM, Martinez-Chantar ML, Shelly CL. S-adenosylmethionine metabolism and liver disease. Ann Hepatol. 2013;12(2):183-9.
  81. Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol. 2012;57(5):1097-109. doi: 10.1016/j.jhep.2012.04.041
  82. Fiorelli G. S-Adenosylmethionine in the treatment of intrahepatic cholestasis of chronic liver disease: a field trial. Curr Ther Res. 1999;60:335-48. doi: 10.1016/S0011-393X(99)80010-1
  83. Барановский А.Ю., Райхельсон К.Л., Марченко Н.В. Применение S-аденозилметионина (Гептрала®) в терапии больных неалкогольным стеатогепатитом. Клин. перспективы гастроэнтерологии, гепатологии. 2010;9(1):3-10 [Baranovsky AY, Raykhelson KL, Marchenko NV. S-adenosylmethionine (Heptral®) in treatment of patients with non-alcoholic steatohepatitis. Klin. perspektivy gastroenterologii, gepatologii. 2010;9(1):3-10 (In Russ.)].
  84. Virukalpattigopalratnam MP, Singh T, Ravishankar AC. Heptral® (Ademetionine) in intrahepatic cholestasis due to chronic non-alcoholic liver disease: subgroup analysis of results of a multicentre observational study in India. J Clin Exp Hepatol. 2014;4(Suppl. 2):S33. doi: 10.1016/j.jceh.2014.02.071
  85. Boming L. Observation of efficacy of ademetionine for treating non-alcoholic fatty liver disease. Chin J Hepatol. 2011;16(4):350-1.

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies